BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...chief legal and administrative officer, effective May 11. She was SVP and general counsel of Revance Therapeutics Inc....
BioCentury | Dec 5, 2019
Financial News

Follow-on Roundup: Arrowhead, Kodiak, Relmada, Revance

...Since market close on Tuesday, Arrowhead, Kodiak, Relmada and Revance raised a total of $718.5 million...
...priced at $30 a share, a 13% discount. Underwriters were Jefferies, SVB Leerink, and Guggenheim. Revance Therapeutics Inc....
...toxin type A compounds for therapeutic and aesthetic use. Val Kennedy, Associate Editor Arrowhead Pharmaceuticals Inc. Relmada Therapeutics Inc. Revance Therapeutics Inc. Kodiak...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...VP of medical affairs of the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD). Revance Therapeutics Inc....
...Staff Writers Xenikos B.V. Alligator Bioscience AB Biocon Ltd. Intercept Pharmaceuticals Inc. Nektar Therapeutics Agios Pharmaceuticals Inc. Accelerate Diagnostics Inc. Caraway Therapeutics Inc. Tricida Inc. Revance Therapeutics Inc. Poxel...
BioCentury | Oct 15, 2019
Company News

Management tracks: Browne out as Revance CEO; plus CytomX, Aligos, Angion, Savonix and Global Cancer Technology

...the University of California San Diego Moores Cancer Center. Jonathan Block, Associate Editor Angion Biomedica Corp. CytomX Therapeutics Inc. Revance Therapeutics Inc. Aligos...
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...has hired Atul Mahableshwarkar as SVP, drug development. He was previously VP, clinical development, at Revance Therapeutics Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:SELB) 1/23/19 $33.3 $64.0 $80.2 25% Kindred Biosciences Inc. (NASDAQ:KIN) 1/18/19 $46.0 $368.2 $324.9 -12% Revance Therapeutics Inc....
BioCentury | Jun 26, 2019
Product Development

AbbVie chooses revenue over innovation with Allergan takeout

...threaten that position. FDA approved competing product Jeuveau prabotulinumtoxinA from Evolus Inc. (NASDAQ:EOLS) in February. Revance Therapeutics Inc....
...for Injection (RT002) for regulatory approval this year to treat moderate to severe glabellar lines. Revance...
...NYSE:JNJ), New Brunswick, N.J. Mylan N.V. (NASDAQ:MYL), Canonsburg, Penn. Reata Pharmaceuticals Inc. (NASDAQ:RETA), Irving, Texas Revance Therapeutics Inc....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Inc. (NASDAQ:REGN) / Sanofi (Euronext:SAN; NASDAQ:SNY) Praluent alirocumab First-line treatment of hyperlipidemia PDUFA date 4/29/19 Revance Therapeutics Inc....
BioCentury | Mar 27, 2019
Company News

Management tracks: Epic, Axcella, KalVista

...Allouche as CFO. He was principal accounting officer, head of finance and corporate controller of Revance Therapeutics Inc....
BioCentury | Jan 18, 2019
Finance

Broken window

...in a follow-on. Acceleron Pharma Inc. (NASDAQ:XLRN), Stemline Therapeutics Inc. (NASDAQ:STML), Mirati Therapeutics Inc. (NASDAQ:MRTX), Revance Therapeutics Inc....
Items per page:
1 - 10 of 88
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...chief legal and administrative officer, effective May 11. She was SVP and general counsel of Revance Therapeutics Inc....
BioCentury | Dec 5, 2019
Financial News

Follow-on Roundup: Arrowhead, Kodiak, Relmada, Revance

...Since market close on Tuesday, Arrowhead, Kodiak, Relmada and Revance raised a total of $718.5 million...
...priced at $30 a share, a 13% discount. Underwriters were Jefferies, SVB Leerink, and Guggenheim. Revance Therapeutics Inc....
...toxin type A compounds for therapeutic and aesthetic use. Val Kennedy, Associate Editor Arrowhead Pharmaceuticals Inc. Relmada Therapeutics Inc. Revance Therapeutics Inc. Kodiak...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...VP of medical affairs of the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD). Revance Therapeutics Inc....
...Staff Writers Xenikos B.V. Alligator Bioscience AB Biocon Ltd. Intercept Pharmaceuticals Inc. Nektar Therapeutics Agios Pharmaceuticals Inc. Accelerate Diagnostics Inc. Caraway Therapeutics Inc. Tricida Inc. Revance Therapeutics Inc. Poxel...
BioCentury | Oct 15, 2019
Company News

Management tracks: Browne out as Revance CEO; plus CytomX, Aligos, Angion, Savonix and Global Cancer Technology

...the University of California San Diego Moores Cancer Center. Jonathan Block, Associate Editor Angion Biomedica Corp. CytomX Therapeutics Inc. Revance Therapeutics Inc. Aligos...
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...has hired Atul Mahableshwarkar as SVP, drug development. He was previously VP, clinical development, at Revance Therapeutics Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:SELB) 1/23/19 $33.3 $64.0 $80.2 25% Kindred Biosciences Inc. (NASDAQ:KIN) 1/18/19 $46.0 $368.2 $324.9 -12% Revance Therapeutics Inc....
BioCentury | Jun 26, 2019
Product Development

AbbVie chooses revenue over innovation with Allergan takeout

...threaten that position. FDA approved competing product Jeuveau prabotulinumtoxinA from Evolus Inc. (NASDAQ:EOLS) in February. Revance Therapeutics Inc....
...for Injection (RT002) for regulatory approval this year to treat moderate to severe glabellar lines. Revance...
...NYSE:JNJ), New Brunswick, N.J. Mylan N.V. (NASDAQ:MYL), Canonsburg, Penn. Reata Pharmaceuticals Inc. (NASDAQ:RETA), Irving, Texas Revance Therapeutics Inc....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Inc. (NASDAQ:REGN) / Sanofi (Euronext:SAN; NASDAQ:SNY) Praluent alirocumab First-line treatment of hyperlipidemia PDUFA date 4/29/19 Revance Therapeutics Inc....
BioCentury | Mar 27, 2019
Company News

Management tracks: Epic, Axcella, KalVista

...Allouche as CFO. He was principal accounting officer, head of finance and corporate controller of Revance Therapeutics Inc....
BioCentury | Jan 18, 2019
Finance

Broken window

...in a follow-on. Acceleron Pharma Inc. (NASDAQ:XLRN), Stemline Therapeutics Inc. (NASDAQ:STML), Mirati Therapeutics Inc. (NASDAQ:MRTX), Revance Therapeutics Inc....
Items per page:
1 - 10 of 88